BioinfometricsBioinfometrics logo mark — DNA double helix encoded as a financial candlestick chart on an upward trend axis. The dual-read mark simultaneously represents molecular biology and market data intelligence.

Bioinfometrics

HHS Opened Six Peptides to Compounding. The Trial Register Lists Five Trials of Them, None Finished

On October 30, HHS said it will not act against pharmacies compounding BPC-157, TB-500, MOTS-c, epitalon, KPV and semax. We counted the human trials behind them in ClinicalTrials.gov and PubMed.

Illustration of six vials on a shelf held up by a single amber post above an empty, dashed foundation
Martin DAVILABy Martin DAVILA11/3/20266

On October 30 the Federal Register published a notice from the Secretary of Health and Human Services: HHS will not take enforcement action against licensed pharmacies, federal facilities or physicians that compound six peptides while FDA decides, through rulemaking, whether to add them to the list of substances pharmacies may compound. The six are BPC-157, TB-500, MOTS-c, epitalon, KPV and semax.

None of the six is an approved drug in the US. The notice says HHS acted because of "significant interest" in these peptides. We looked for the other half of the question: how much human evidence exists.

How many human trials test these peptides?

We searched ClinicalTrials.gov, the US register of clinical studies, for each peptide name and its common spellings, then read every record that came back. We kept only interventional trials that give the named peptide to people. We did the same for PubMed records tagged as clinical trials.

The six peptides have five registered trials between them, and none has finished.

Interventional trials that give the named peptide to people, by peptide. Registered trials from ClinicalTrials.gov; published reports from PubMed records tagged as clinical trials.

Registered trials (ClinicalTrials.gov)Published trial reports (PubMed)

Source: ClinicalTrials.gov API v2 and NCBI PubMed E-utilities, queried November 2, 2026. We read each record and excluded studies that only measure a peptide in blood (most MOTS-c hits), multi-ingredient supplements and serums, and false matches (a PubMed TB-500 hit about tuberculosis). Counts are records, not patients.

View data
peptideregisteredpublished
BPC-15730
TB-50010
MOTS-c10
Semax04
Epitalon01
KPV00

Five registered trials give one of the six peptides to people. Three test BPC-157: a Phase 2 trial in hamstring strain (recruiting, 120 planned participants), a Phase 1 trial after rotator cuff surgery (not yet recruiting) and a 2015 Phase 1 safety trial whose status the register lists as unknown. One tests TB-500 and one tests MOTS-c. Three of the five, the hamstring BPC-157 trial and the TB-500 and MOTS-c trials, list the same sponsor, Hudson Biotech, and all three started in February 2026. None of the five reports results. Epitalon, KPV and semax have no registered trial that tests them alone.

PubMed tells a similar story from the other side. Across the six peptides it holds five records tagged as clinical trials that give the peptide to patients. Four are semax studies in Russian-language journals, published between 1997 and 2018, mostly in stroke. One is a 2002 epitalon study in retinitis pigmentosa. For comparison, the same ClinicalTrials.gov search returns 822 study records for semaglutide.

What did FDA's advisers and staff say?

The peptides went to FDA's Pharmacy Compounding Advisory Committee on July 23 and 24. According to accounts of the meeting by the FDA Law Blog and AJMC, which agree on the counts, the committee voted for all six, each time with 7 or 8 votes in favour, 4 to 6 against and one or two abstentions. A seventh peptide, emideltide, was voted down. Both accounts report that FDA review staff recommended against adding the peptides, citing uncertainty about what the substances are, short and small studies, and a lack of adverse event data.

The HHS notice says FDA may still propose adding some or all of the peptides "based on the available evidence". Until then, the interim policy applies.

What does the policy allow?

The notice itself is two pages. The conditions are in an appendix that HHS posted on its website, and law firm summaries describe them. Each compounded product may contain one listed peptide only, so blends are out. It needs a patient-specific prescription. The bulk peptide must come from an FDA-registered manufacturer with a certificate of analysis. Routes are restricted per peptide: semax is intranasal only, KPV is topical or oral, and BPC-157 may be injected, taken orally or applied to skin. Serious adverse events must be reported to FDA's MedWatch. The policy does not cover larger outsourcing facilities or products sold as research chemicals.

Written comments are open on docket HHS-OASH-2026-0496 for two weeks after publication, which by our count means until November 13.

Limits

Name searches miss trials that use code names, and they can catch unrelated records, so we read each one; another reader could classify a borderline record differently. ClinicalTrials.gov does not hold every trial in the world, in particular trials registered only in Russia or China, where some of these peptides have been studied. Our PubMed count relies on the clinical trial tag, which misses some trials and includes some that only measure a peptide. We could not open the HHS appendix directly, so the conditions above come from the Baker law firm and FDA Law Blog summaries, which agree with each other. Counting trials says nothing about whether a peptide works; it says how much has been tested in people.

Sources

  1. Federal Register, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, 91 FR 68526, October 30, 2026: scope, docket number, two-week comment period, possible future rulemaking.
  2. ClinicalTrials.gov, API v2, queried November 2, 2026: NCT07437547, NCT07803250, NCT02637284 (BPC-157); NCT07487363 (TB-500); NCT07505745 (MOTS-c). Excluded after reading: NCT07752381 (multi-ingredient gummies) and NCT07888595 (multi-peptide topical serum).
  3. NCBI PubMed via E-utilities, queried November 2, 2026, filtered to clinical trial or randomized controlled trial publication types: semax PMIDs 29798983, 18379501, 10741256, 11517472; epitalon PMID 12195242.
  4. Baker Hostetler, HHS issues enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, October 28, 2026: conditions and routes.
  5. FDA Law Blog, PCAC approves four bulk drug substances and PCAC adds two more, July 2026; AJMC, FDA panel backs 6 peptides for compounding: vote counts and FDA staff recommendations. These are secondary accounts of the meeting.
  6. Related: AI-discovered drugs pass Phase I often and FDA has approved 46 novel drugs by October 9.

Found this article helpful? Share it with your network!

Recommended Reading

Discussion (0)

Sign in to join the conversation and share your thoughts

No comments yet. Be the first to start the discussion!